Top 100 UK law firm, BDB Pitmans, has supported leading biotechnology company Verici Dx (Verici) with its fundraise of over £10 million of capital to expand the company’s current offering and facilitate the exploration of further opportunities for growth.
Founded in 2020, AIM-listed Verici is an immuno-diagnostics development company, focused predominantly on advanced next-generation sequencing to improve kidney transplantation success rates. Verici develops clinical diagnostics for organ transplants, using innovative technology to provide personalised platforms designed to assist clinicians caring for transplant patients. The organisation uses AI to track biological pathway signals which highlight increased risk of injury, rejection or graft failure.
BDB Pitmans team was led by corporate partner Nick McCarthy and lead fee earner, corporate legal director Jude Layas. Additional support was provided by corporate solicitor Zoe Symes.
Nick McCarthy, partner, commented:
‘It was a pleasure to work with Verici once again and we are delighted to have advised on another successful ECM transaction. Verici are at the forefront of modern biotechnology and these additional funds will help to drive their important and pioneering work. We are very proud to have played a part in supporting their progress.’
